Company Overview and News

 
Kiwi pharmacy firm Green Cross Health not fazed by Chemist Warehouse expansion

2018-04-06 nzherald.co.nz
The healthcare company which operates Unichem and Life Pharmacy stores is optimistic new entrant Chemist Warehouse will increase its business.
Upvote Downvote

1
Brokers' Picks 2018: Hot stocks for the new year

2017-12-31 nzherald.co.nz
Brokers have picked a diverse mix of stocks for 2018, in many cases opting for those that have underperformed in the last year or so.
Upvote Downvote

1
Brokers Picks: The 2017 results look good

2017-12-31 nzherald.co.nz
It has been a good year for local equities. In fact we're not far from being able to call it a good decade with the NZX bull-run moving into its ninth year in 2018.
Upvote Downvote

 
NZ shares gain, Ryman hits record

2017-11-27 nzherald.co.nz
New Zealand shares rose as Ryman Healthcare climbed to a new record after last week's strong earnings result, while upcoming index reweightings stoked demand for Fisher & Paykel Healthcare while weighing on Contact Energy.
Upvote Downvote

 
Consumer NZ inquiry reveals eye-watering prices for antihistamines

2017-10-04 nzherald.co.nz
Allergy sufferers can slash their antihistamine bill in half by shopping around, a Consumer NZ investigation has found.
Upvote Downvote

 
NZ shares rise, led by Arvida

2017-05-24 nzherald.co.nz
Arvida Group led the New Zealand share market higher as investors were cheered by positive earnings reports and - like much of Asia - shrugged off news Moody's Investors Service cut its sovereign credit rating on China.
Upvote Downvote

 
Brokers picks - the shares that could soar in 2017

2016-12-25 nzherald.co.nz
Some undervalued "blue chip" companies and a selection of small cap stocks dominate our broker picks for the year ahead.
Upvote Downvote

 
Shares mixed as market outperforms Oz

2016-11-28 nzherald.co.nz
NZ shares were mixed as Orion Health Group plunged following its first-half results, while Sky Network Television and Contact Energy gained.
Upvote Downvote

 
NZ shares mixed as Orion plunges

2016-11-28 nzherald.co.nz
New Zealand shares were mixed as Orion Health Group plunged following its first half results, while Sky Network Television and Contact Energy gained.
Upvote Downvote

 
Green Cross Health profits stall

2016-11-28 nzherald.co.nz
Green Cross Health, the listed medical services provider, saw its first-half operating profit stall despite a large one-off gain which boosted its statutory net profit 24 per cent.
Upvote Downvote

 
Loyalty cards: The big reshuffle

2016-10-07 nzherald.co.nz
Millions of loyalty cards are being reshuffled this month as schemes form new alliances in what experts say is an increasingly intense battle to keep customers true.
Upvote Downvote

 
Green Cross to increase in-home care to elderly, says government must improve funding

2016-08-03 nbr.co.nz
Green Cross Health, the listed medical services provider, says it is looking to offer more in-home care for elderly private patients but says the government must improve the public funding system.
Upvote Downvote

 
Green Cross acquisitions drive 18% lift in annual profit

2016-05-24 nbr.co.nz
Green Cross Health [NZX: GXH] lifted annual profit 18% as the primary healthcare group added to its pharmacy chain and expanded into community nursing and medical services.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...